MYD88 and Sepsis: This study confirmed that ulinastatin can achieve intestinal mucosal barrier protection in sepsis by inhibiting TLR4/MyD88/NF-κB anti-inflammatory signal transduction and reducing inflammation-related cascade reactions and finally provides a reliable theoretical basis for the use of ulinastatin in the clinic.